[HTML][HTML] Infliximab biosimilar CT-P13 therapy in patients with Takayasu arteritis with low dose of glucocorticoids: a prospective single-arm study
To evaluate the efficacy and safety of infliximab biosimilar CT-P13 in patients with active
Takayasu arteritis (TAK). In this single-center open-label trial, patients with active TAK …
Takayasu arteritis (TAK). In this single-center open-label trial, patients with active TAK …
Infliximab biosimilar CT-P13 therapy in patients with Takayasu arteritis with low dose of glucocorticoids: a prospective single-arm study
EH Park, EY Lee, YJ Lee, YJ Ha… - Rheumatology …, 2018 - snucm.elsevierpure.com
To evaluate the efficacy and safety of infliximab biosimilar CT-P13 in patients with active
Takayasu arteritis (TAK). In this single-center open-label trial, patients with active TAK …
Takayasu arteritis (TAK). In this single-center open-label trial, patients with active TAK …
Infliximab biosimilar CT-P13 therapy in patients with Takayasu arteritis with low dose of glucocorticoids: a prospective single-arm study.
EH Park, EY Lee, YW Song, YJ Lee… - Rheumatology …, 2018 - search.ebscohost.com
To evaluate the efficacy and safety of infliximab biosimilar CT-P13 in patients with active
Takayasu arteritis (TAK). In this single-center open-label trial, patients with active TAK …
Takayasu arteritis (TAK). In this single-center open-label trial, patients with active TAK …
Infliximab biosimilar CT-P13 therapy in patients with Takayasu arteritis with low dose of glucocorticoids: a prospective single-arm study.
EH Park, EY Lee, YJ Lee, YJ Ha, WH Yoo… - Rheumatology …, 2018 - europepmc.org
To evaluate the efficacy and safety of infliximab biosimilar CT-P13 in patients with active
Takayasu arteritis (TAK). In this single-center open-label trial, patients with active TAK …
Takayasu arteritis (TAK). In this single-center open-label trial, patients with active TAK …
[HTML][HTML] Infliximab biosimilar CT-P13 therapy in patients with Takayasu arteritis with low dose of glucocorticoids: a prospective single-arm study
EH Park, EY Lee, YJ Lee, YJ Ha, WH Yoo… - Rheumatology …, 2018 - ncbi.nlm.nih.gov
To evaluate the efficacy and safety of infliximab biosimilar CT-P13 in patients with active
Takayasu arteritis (TAK). In this single-center open-label trial, patients with active TAK …
Takayasu arteritis (TAK). In this single-center open-label trial, patients with active TAK …
Infliximab biosimilar CT-P13 therapy in patients with Takayasu arteritis with low dose of glucocorticoids: a prospective single-arm study
EH Park, EY Lee, YJ Lee, YJ Ha… - Rheumatology …, 2018 - search.proquest.com
To evaluate the efficacy and safety of infliximab biosimilar CT-P13 in patients with active
Takayasu arteritis (TAK). In this single-center open-label trial, patients with active TAK …
Takayasu arteritis (TAK). In this single-center open-label trial, patients with active TAK …
Infliximab biosimilar CT-P13 therapy in patients with Takayasu arteritis with low dose of glucocorticoids: a prospective single-arm study
EH Park, EY Lee, YJ Lee, YJ Ha… - Rheumatology …, 2018 - pubmed.ncbi.nlm.nih.gov
To evaluate the efficacy and safety of infliximab biosimilar CT-P13 in patients with active
Takayasu arteritis (TAK). In this single-center open-label trial, patients with active TAK …
Takayasu arteritis (TAK). In this single-center open-label trial, patients with active TAK …
Infliximab biosimilar CT-P13 therapy in patients with Takayasu arteritis with low dose of glucocorticoids: a prospective single-arm study
EH Park, EY Lee, YJ Lee, YJ Ha, WH Yoo… - Rheumatology …, 2018 - cir.nii.ac.jp
抄録< jats: title> Abstract</jats: title>< jats: p> To evaluate the efficacy and safety of infliximab
biosimilar CT-P13 in patients with active Takayasu arteritis (TAK). In this single-center open …
biosimilar CT-P13 in patients with active Takayasu arteritis (TAK). In this single-center open …